Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators. Gallois C, et al. Among authors: mulot c. Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19. Clin Cancer Res. 2018. PMID: 29921730 Clinical Trial.
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P. Boige V, et al. Among authors: mulot c. J Clin Oncol. 2010 May 20;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385995 Clinical Trial.
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.
Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G. Vacchelli E, et al. Among authors: mulot c. Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29. Science. 2015. PMID: 26516201
Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia.
Tcheandjieu C, Lesueur F, Sanchez M, Baron-Dubourdieu D, Guizard AV, Mulot C, Laurent-Puig P, Schvartz C, Truong T, Guenel P. Tcheandjieu C, et al. Among authors: mulot c. Int J Cancer. 2016 Aug 1;139(3):617-27. doi: 10.1002/ijc.30088. Epub 2016 Mar 30. Int J Cancer. 2016. PMID: 26991144 Free article.
A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.
Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V. Garrigou S, et al. Among authors: mulot c. Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1. Clin Chem. 2016. PMID: 27251038
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators. Taieb J, et al. Among authors: mulot c. Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687. Ann Oncol. 2017. PMID: 28031175 Free article. Clinical Trial.
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanan A. Garlan F, et al. Among authors: mulot c. Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2. Clin Cancer Res. 2017. PMID: 28576867
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators. Taieb J, et al. Among authors: mulot c. JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12. JAMA Oncol. 2018. PMID: 29167892 Free PMC article.
Circadian genes and risk of prostate cancer: Findings from the EPICAP study.
Wendeu-Foyet MG, Koudou Y, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Bacq D, Deleuze JF, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F. Wendeu-Foyet MG, et al. Among authors: mulot c. Int J Cancer. 2019 Oct 1;145(7):1745-1753. doi: 10.1002/ijc.32149. Epub 2019 Feb 12. Int J Cancer. 2019. PMID: 30665264 Free article.
62 results